Asston Pharmaceuticals IPO Details
| IPO Open Date: | July 9, 2025 |
| IPO Close Date: | July 11, 2025 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹115 to ₹123 Per Share |
| Issue Size: | Approx ₹27.56 Crores |
| Fresh Issue: | Approx ₹27.56 Crores |
| Issue Type: | Book Build Issue |
| IPO Listing: | BSE SME |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Asston Pharmaceuticals IPO Market Lot
The Asston Pharmaceuticals IPO minimum market lot is 2,000 shares with ₹2,46,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,46,000 |
| Retail Maximum | 2 | 2,000 | ₹2,46,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,69,000 |
Asston Pharmaceuticals IPO Dates
The Asston Pharmaceuticals IPO date is July 9 and the close date is July 11. The Asston Pharmaceuticals IPO allotment will be finalized on July 14 and the IPO listing on July 16.
| IPO Open Date: | July 9, 2025 |
| IPO Close Date: | July 11, 2025 |
| Basis of Allotment: | July 14, 2025 |
| Refunds: | July 15, 2025 |
| Credit to Demat Account: | July 15, 2025 |
| IPO Listing Date: | July 16, 2025 |
Promoters of Asston Pharmaceuticals IPO
The promoters of the company are Dr. Ashish Narayan Sakalkar, Saili Jayaram More and Sachin Chandrakant Badakh.
About Asston Pharmaceuticals IPO
Asston Pharmaceuticals Limited was established in 2019 is one of the growing companies engaged in the business of pharmaceuticals, as well as involved in the exporting of the healthcare products globally. The company’s portfolio consists of wide range of products such as tablets, capsules, sachets, and syrups. The company offers various products in therapeutic categories include analgesics, antibiotics, antifungals, vitamins, and more. Asston pharmaceutical is involved in the manufacturing of pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis mostly working on a principle-to-principle approach with various marketers. Asston pharmaceuticals ltd is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing. The company’s portfolio consists of many products such as Albendazole USP 400 mg, Diclofenac 100 mg, Ibuprofen, paracetamol, and Ferrovit Syrup. The company includes 46 Permanent employees and 6 contractual employees as of 3 July, 2025.
Asston Pharmaceuticals IPO Company Financial Report
The company reported revenue of ₹25.61 crores in 2025 against ₹15.84 crores in 2024. The company reported profit of ₹4.33 crores in 2025 against profit of ₹1.36 crores in 2024.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2023 | ₹7.19 | ₹5.78 | ₹1.06 | ₹13.69 |
| 2024 | ₹15.84 | ₹14.02 | ₹1.36 | ₹20.26 |
| 2025 | ₹25.61 | ₹19.91 | ₹4.33 | ₹28.12 |
| May 2025 | ₹6.21 | ₹4.44 | ₹1.32 | ₹31.83 |
Asston Pharmaceuticals IPO Valuation – FY2025
Check Asston Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 50.56% |
| ROCE: | 51.25% |
| EBITDA Margin: | 24.60% |
| PAT Margin: | 17.27% |
| Debt to equity ratio: | 0.68 |
| Earning Per Share (EPS): | ₹6.90 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 40.36% |
| Net Asset Value (NAV): | ₹17.09 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Shelter Pharma Limited | 6.26 | 6.70 | 16.94% | 36.96 | – Cr. |
| Bafna Pharmaceuticals Limited | 1.76 | 51.38 | 4.89% | 35.86 | – Cr. |
| Trident Lifeline Limited | 11.35 | 25.29 | 19.85% | 57.16 | – Cr. |
Objects of the Issue
- Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
- Funding the incremental working capital requirements of the Company
- Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
- General Corporate Purposes
Asston Pharmaceuticals IPO Review
- IPO Watch – May Apply
- Canara Bank –
- DRChoksey FinServ –
- Emkay Global –
- Hem Securities –
- IDBI Capital –
- Marwadi Shares –
- Nirmal Bang –
- SBICAP Securities –
- Sharekhan –
- SMC Global –
- Sushil Finance –
- Swastika Investmart –
- Ventura Securities –
- Geojit –
- Reliance Securities –
- Capital Market –
- BP Wealth –
- ICICIdirect –
- Choice Broking –
Asston Pharmaceuticals IPO Registrar
Maashitla
Securities
Private
Limited
Phone:
+91-11-45121795-96
Email:
[email protected]
Website:
https://maashitla.com/allotment-status/public-issues
IPO Lead Managers aka Merchant Bankers
- Sobhagya Capital Options Ltd
Company Address
Asston
Pharmaceuticals
Limited
4th
Floor,
Office
No.
A-431
Balaji
Bhavan,
Plot
No
42A
Sector-11
CBD
Belapur,
Navi
Mumbai,
Thane
Navi
Mumbai, Maharashtra,
400614
Phone: +91
22
49731411
Email: [email protected]
Website: http://www.asstonpharmaceuticals.com/
Asston Pharmaceuticals IPO FAQs
What is Asston Pharmaceuticals IPO?
When Asston Pharmaceuticals IPO will open for subscription?
What is Asston Pharmaceuticals IPO Investors Portion?
How to Apply the Asston Pharmaceuticals IPO?
What is Asston Pharmaceuticals IPO Issue Size?
What is Asston Pharmaceuticals IPO Price Band?
What is Asston Pharmaceuticals IPO Lot Size?
What is the Asston Pharmaceuticals IPO Allotment Date?
What is the Asston Pharmaceuticals IPO Listing Date?
Note: The Asston Pharmaceuticals IPO price band and date are officially announced. The (Asston Pharmaceuticals IPO grey market premium) will be added to the IPO GMP page as it will start).
